RT-102 repeat-dose Phase 1 meets endpoints; 91% delivery success, high bioavailability, supports Phase 2

Rani Therapeutics Holdings, Inc.

No serious adverse events; all 10 participants completed 7-day daily dosing.
RaniPill GO delivered PTH with 91% overall success; Day 7 success rate 100%.
RT-102 showed high PTH bioavailability vs subcutaneous injection in Part 1.
Company expects to initiate Phase 2 trial of RT-102 in osteoporosis in H2 2023.
Over 185 RaniPill capsules administered in clinical studies; platform advancing for multiple programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.